Literature DB >> 2890073

Disturbances of sleep and wakefulness associated with the use of antihypertensive agents.

J M Monti1.   

Abstract

Sleep disturbances are frequently associated with the use of antihypertensive drugs. They are observed mainly during the administration of drugs that affect central adrenergic mechanisms. Beta-adrenoceptor antagonists which readily penetrate into the brain (propranolol, pindolol) increase wakefulness and/or decrease REM sleep. Alpha 2-adrenoceptor agonists (clonidine, guanfacine) markedly reduce the duration of REM sleep. The catecholamine depleting agent reserpine increases REM sleep during single or repeated-dose administration, while the MAOI phenelzine shows opposite effects. The 5-HT2 antagonist ritanserin, which is chemically related to the antihypertensive agent ketanserin, increases slow wave sleep while REM sleep is decreased. Sleep disturbances have not been reported during the administration of calcium entry antagonists. However, they seem to modify the effects of hypnotics and CNS stimulants. There are no formal studies on the effects of angiotensin converting enzyme inhibitors and vasodilators on sleep in man.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890073     DOI: 10.1016/0024-3205(87)90471-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  [Sleep medicine differential diagnostics in psychiatry and psychotherapy].

Authors:  T Pollmächer; T C Wetter; S Happe; K Richter; J Acker; D Riemann
Journal:  Nervenarzt       Date:  2014-01       Impact factor: 1.214

2.  Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy.

Authors:  Y Yamada; F Shibuya; J Hamada; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

3.  NREM sleep stage transitions control ultradian REM sleep rhythm.

Authors:  Akifumi Kishi; Hideaki Yasuda; Takahisa Matsumoto; Yasushi Inami; Jun Horiguchi; Masako Tamaki; Zbigniew R Struzik; Yoshiharu Yamamoto
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

Review 4.  Drug-induced sleep disturbances. Focus on nonpsychotropic medications.

Authors:  M Novak; C M Shapiro
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 5.  The Role of Sleep and Sleep Disorders in the Development, Diagnosis, and Management of Neurocognitive Disorders.

Authors:  Michelle A Miller
Journal:  Front Neurol       Date:  2015-10-23       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.